Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 11:2021:6678142.
doi: 10.1155/2021/6678142. eCollection 2021.

Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications

Ana-Maria Singeap  1   2 , Carol Stanciu  2 , Laura Huiban  1   2 , Cristina Maria Muzica  1   2 , Tudor Cuciureanu  1   2 , Irina Girleanu  1   2 , Stefan Chiriac  1   2 , Sebastian Zenovia  1   2 , Robert Nastasa  1   2 , Catalin Sfarti  1   2 , Camelia Cojocariu  1   2 , Anca Trifan  1   2
Affiliations
Review

Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications

Ana-Maria Singeap et al. Can J Gastroenterol Hepatol. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) has a rising prevalence worldwide. Its potential for evolution towards liver cirrhosis and hepatocellular carcinoma, as well as associations with extrahepatic manifestations, represents a double burden for patients and physicians alike. Recently, there has been increasing evidence of the association between NAFLD and a number of endocrinopathies, such as hypothyroidism, polycystic ovarian syndrome (PCOS), hypopituitarism, growth hormone deficiency (GHD), hypogonadism, and hypercortisolism. Definite correlations are supported by clear evidence so far, but further studies are needed in order to completely clarify the pathogenic mechanisms and, especially, to identify therapeutic implications. In this review, we present the main relationships between NAFLD and endocrinopathies, emphasizing the reciprocal causality, evolutive interconnections, and current clinical scenarios of presentations of which the clinicians should be aware.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Lonardo A., Mantovani A., Lugari S., Targher G. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. International Journal of Molecular Sciences. 2019;20:11–2841. doi: 10.3390/ijms20112841. - DOI - PMC - PubMed
    1. Younossi Z., Tacke F., Arrese M., et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. doi: 10.1002/hep.30251. - DOI - PubMed
    1. Sayiner M., Koenig A., Henry L., Younossi Z. M. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clinics in Liver Disease. 2016;20(2):205–214. doi: 10.1016/j.cld.2015.10.001. - DOI - PubMed
    1. Asfari M. M., Sarmini M. T., Baidoun F., et al. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterology. 2020;7(1) doi: 10.1136/bmjgast-2019-000352.e000352 - DOI - PMC - PubMed
    1. Stanciu C., Trifan A. Nonalcoholic steatohepatitis: the mainstay of clinical hepatology. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2019;123(3):379–383.

LinkOut - more resources